ReviewInterventional cardiology (London, England)2018
Anticoagulant Therapy for Acute Coronary Syndromes.
Review in Interventional cardiology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Triple Therapy: A Safe, Cost-Effective Regimen of Heparin, Aspirin and Clopidogrel for Managing Intracranial Vessel Occlusions in Patients With Acute Ischemic Stroke Who Are Ineligible for Intravenous Thrombolytics and Endovascular Thrombectomy.Stroke (Hoboken, N.J.) · 2026Article
- Transfusion requirements in acute coronary syndrome patients undergoing thrombolysis or anticoagulation: A retrospective cohort study.Bioinformation · 2026Article
- Article
- Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study.Journal of pharmaceutical policy and practice · 2024Article
- Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India.Cardiology and therapy · 2023Review
- Friend or Foe: Factor XII Deficiency Discovered Incidentally during Management of NSTEMI.Case reports in hematology · 2023Article
- Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population.Cardiology and therapy · 2022Article
- Fondaparinux: A cornerstone drug in acute coronary syndromes.World journal of cardiology · 2022Review
- Association of Prolonged Emergency Department Length of Stay with Adverse Events in Patients with Non-ST-Elevation Acute Coronary Syndrome.Open access emergency medicine : OAEM · 2022Article
- Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine.Pharmaceutics · 2021Review
- Systemic Review of Biodegradable Nanomaterials in Nanomedicine.Nanomaterials (Basel, Switzerland) · 2020Review
- Cost-Effectiveness and Cost-Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulation in conjunction with antiplatelet therapy is central to the management of acute coronary syndromes (ACS). When used effectively it is associated with a reduction in recurrent ischaemic events including myocardial infarction and stent thrombosis as well as a reduction in death. Effective ischaemic risk reduction whilst balancing bleeding risk remains a clinical challenge. This article reviews the current available evidence for anticoagulation in ACS and recommendations from the European Society of Cardiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.